Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) EBT (2017 - 2025)

Puma Biotechnology's EBT history spans 9 years, with the latest figure at -$18.7 million for Q4 2025.

  • For Q4 2025, EBT fell 252.6% year-over-year to -$18.7 million; the TTM value through Sep 2025 reached $30.9 million, up 25.33%, while the annual FY2024 figure was $24.1 million, 6.29% up from the prior year.
  • EBT reached -$18.7 million in Q4 2025 per PBYI's latest filing, down from $9.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $20.6 million in Q3 2024 to a low of -$44.6 million in Q3 2021.
  • Average EBT over 5 years is $903650.0, with a median of $2.8 million recorded in 2023.
  • Peak YoY movement for EBT: soared 2150.85% in 2023, then tumbled 396.83% in 2024.
  • A 5-year view of EBT shows it stood at $4.4 million in 2021, then tumbled by 230.05% to -$5.8 million in 2022, then skyrocketed by 321.94% to $12.8 million in 2023, then decreased by 4.42% to $12.2 million in 2024, then crashed by 252.6% to -$18.7 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's EBT are -$18.7 million (Q4 2025), $9.2 million (Q3 2025), and $6.2 million (Q2 2025).